Publications by authors named "J Q Cel Rosso"
Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes. Patients received Tapinarof or vehicle cream QD for 8 weeks.
View Article and Find Full Text PDFArticle Synopsis
- Topical clindamycin phosphate/adapalene/benzoyl peroxide (CAB) gel is approved for treating acne in patients 12 and older, and post hoc analyses examined its effectiveness in younger patients with acne.
- Data from two studies showed that CAB significantly improved treatment success and reduced acne lesions in adolescents compared to a vehicle gel, with 51.5% of treated adolescents achieving success versus 24.9% with the vehicle.
- The CAB gel was generally well tolerated, with most adverse events being mild to moderate, and it was effective for younger children as well, with significant lesion reductions observed in all treated children.
The FORWARD Psoriasis Registry: Patient-Reported Outcomes in a Novel Psoriasis Registry and Comparison of Traditional, Dermatologist-Led Enrollment With Web-Based Patient Enrollment.
J Psoriasis Psoriatic Arthritis
November 2024
Article Synopsis
- The FORWARD Psoriasis Registry aims to gather real-world evidence on psoriasis by collecting patient-reported data independent of clinicians.
- The study compares characteristics and treatment outcomes of two groups: those enrolling through a clinician and those self-enrolling online.
- Results showed significant differences between the two groups in disease burden and treatment satisfaction, indicating the importance of diverse data collection methods for understanding psoriasis.
Article Synopsis
- Clindamycin phosphate/adapalene/benzoyl peroxide gel (CAB) is the only approved triple-combination treatment for acne, and a post hoc analysis evaluated its efficacy and safety based on sex.
- In two phase 3 clinical studies, participants aged 9 and older with moderate-to-severe acne were treated with CAB or a placebo for 12 weeks, and outcomes were analyzed by sex regarding treatment success, lesion counts, quality of life, and side effects.
- Results showed that CAB was significantly more effective than the vehicle for both sexes in reducing acne severity and improving quality of life, with no notable differences in safety or efficacy between male and female participants.